ISSCR News


The ISSCR Joins Letter Expressing Concerns Regarding Executive Order on Federal Grantmaking
Policy Kym Kilbourne Policy Kym Kilbourne

The ISSCR Joins Letter Expressing Concerns Regarding Executive Order on Federal Grantmaking

The ISSCR joined more than 50 scientific societies to send a letter to U.S. congressional leaders expressing concerns over provisions in the recent Executive Order (EO) titled “Improving Oversight of Federal Grantmaking.” The letter details how E.O. provisions threaten the long-standing merit-based peer review system that has been the gold standard for supporting cutting-edge research and driving technological innovation. Provisions the letter highlights include those on shifting the review and selection of research awards to political appointees, expansion of “termination for convenience” authority over awarded grants, vague language regarding repeat grant recipients, and the prioritization of institutions with the lowest indirect cost rates. The letter urges Congress to provide necessary oversight at scientific agencies to prevent potentially significant damage to the federal scientific grantmaking process.

Read More
The ISSCR Endorses Joint Associations Group Letter Calling for Continued Support of Essential Research Costs
Policy Kym Kilbourne Policy Kym Kilbourne

The ISSCR Endorses Joint Associations Group Letter Calling for Continued Support of Essential Research Costs

The ISSCR joined over 160 biomedical and other research organizations to urge U.S. House and Senate appropriators to ensure that essential costs of research continue to be adequately supported by the federal government. These costs, currently collectively known as “indirect costs” or “facilities and administrative” support, are essential to performing high quality scientific research and include expenses like physical lab maintenance, utility costs, data processing, and regulatory compliance. The letter urges appropriators to preserve federal support for essential research expenses, to block arbitrary caps on these costs, and to ensure there is a sufficient transition period for agencies and institutions to make necessary changes to effectively transition to any alternative funding model.

Read More
ISSCR Statement on the Scientific and Therapeutic Value of Human Fetal Tissue Research
Policy, Statement Kym Kilbourne Policy, Statement Kym Kilbourne

ISSCR Statement on the Scientific and Therapeutic Value of Human Fetal Tissue Research

The International Society for Stem Cell Research (ISSCR), the largest professional organization of stem cell researchers from around the world, is concerned about a recent statement attributed to NIH that the agency will not renew research grants involving human fetal tissue (HFT), and that research with HFT is not conducted responsibly or transparently. In fact, research with HFT has been indispensable in advancing biomedicine and saving millions of lives, and it continues to play an essential role in accelerating research that benefits patients.

Read More
The ISSCR Partners with Nuffield Council on Bioethics to Compile Global Horizon Scan on Stem Cell Research
Press Release, Policy Kym Kilbourne Press Release, Policy Kym Kilbourne

The ISSCR Partners with Nuffield Council on Bioethics to Compile Global Horizon Scan on Stem Cell Research

The International Society for Stem Cell Research (ISSCR) today announced a new partnership with the Nuffield Council on Bioethics (NCOB) to conduct an ambitious international horizon scan focused on the future of stem cell science and its ethical implications. The initiative will help signal and inform updates to the ISSCR Guidelines for Stem Cell Research and Clinical Translation and guide the Society’s broader public policy agenda.

Read More
The ISSCR Holds Inaugural Regulatory Meeting with Japan’s Pharmaceuticals and Medical Devices Agency and South Korea’s Ministry of Food and Drug Safety 
Policy, Announcements Kym Kilbourne Policy, Announcements Kym Kilbourne

The ISSCR Holds Inaugural Regulatory Meeting with Japan’s Pharmaceuticals and Medical Devices Agency and South Korea’s Ministry of Food and Drug Safety 

On 7 November 2024, the International Society for Stem Cell Research (ISSCR) held its first meeting with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Korea’s Ministry of Food and Drug Safety (MFDS). Held at PMDA’s Tokyo headquarters, the meeting brought together senior officials from PMDA and MFDS alongside ISSCR leaders based in Japan, Korea, and the United States.

At this inaugural meeting, participants convened to discuss key topics related to the:

1) manufacture of human Pluripotent Stem Cell (hPSC) banks as starting materials for allogeneic, PSC-based therapies, and
2) genetic assessment of hPSCs, 3) jurisdictional differences in guidelines for biological Ancillary Materials (AM).

The participants also had the opportunity to gain insights into the regulatory approaches of the PMDA and MFDS regarding PSC-based products.  

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .